Clinical Arterial Spin-Labeling MR Imaging to Screen for Typical and Atypical Neurodegenerative Disease in the New Era of Alzheimer Treatment.
| Publication Type | Case Report |
| Authors | Lee K, Mahmud M, Marx D, Yasen W, Sharma O, Ivanidze J, Zan E, Zhou L, Li Y, de Leon M, Nordvig A, Chiang G |
| Journal | AJNR Am J Neuroradiol |
| Volume | 45 |
| Issue | 5 |
| Pagination | 632-636 |
| Date Published | 05/09/2024 |
| ISSN | 1936-959X |
| Keywords | Alzheimer Disease, Magnetic Resonance Imaging, Neurodegenerative Diseases, Spin Labels |
| Abstract | The clinical standard of care in the diagnosis of neurodegenerative diseases relies on [18F] FDG-PET/CT or PET MR imaging. Limitations of FDG-PET include cost, the need for IV access, radiation exposure, and availability. Arterial spin-labeling MR imaging has been shown in research settings to be useful as a proxy for FDG-PET in differentiating Alzheimer disease from frontotemporal dementia. However, it is not yet widely used in clinical practice, except in cerebrovascular disease. Here, we present 7 patients, imaged with our routine clinical protocol with diverse presentations of Alzheimer disease and other neurodegenerative diseases, in whom arterial spin-labeling-derived reduced CBF correlated with hypometabolism or amyloid/tau deposition on PET. Our case series illustrates the clinical diagnostic utility of arterial spin-labeling MR imaging as a fast, accessible, and noncontrast screening tool for neurodegenerative disease. Arterial spin-labeling MR imaging can guide patient selection for subsequent PET or fluid biomarker work-up, as well as for possible therapy with antiamyloid monoclonal antibodies. |
| DOI | 10.3174/ajnr.A8164 |
| PubMed ID | 38485200 |
| PubMed Central ID | PMC11288532 |